ABSTRACT-Aspergillomarasmine-A and -B (AM-A and -B), which were isolated from the cultured broth of an unidentified fungus N877, showed apparent inhibition against endothelin-converting enzyme (ECE) from bovine endothelial cells as measured by the formation of endothelin-1 (ET-1) converted from big endo thelin-1 (bET-1), with IC50 values of 3.4 and 2.5 pM for AM-A and -B, respectively. EDTA also inhibited ECE (IC50=1.1 pM), but the inhibitions by AM-A, AM-B and EDTA were each abolished by the addition of 10 pM Zn21 to the reaction mixture. In mice, AM-A and -B dose-dependently (10-50 mg/kg, i.v.) caus ed significant prolongation of the latency to sudden death induced by i.v. bET-1 (25 nmol/kg), but not that by ET-1 (5 nmol/kg), accompanied by a decrease in plasma immunoreactive ET-1 formation, while EDTA (24 mg/kg) failed to do so. In mice, the LD50 value of AM-A was calculated to be 159.8 mg/kg, i.v., which was much larger than that of EDTA (28.5 mg/kg, i.v.), indicating the low toxicity of AM-A. AM-A (30 mg/kg, i.v.) also suppressed bET-l-induced hemoconcentration and hypertension in mice and rats, respec tively. These findings suggest that although ECE inhibition by AM-A was mainly attributable to its chelating activity, it showed apparent in vivo activities due to ECE inhibition with low toxicity.
Endothelin-1 (ET-1) is biosynthesized through the con version of its precursor big endothelin-1 (bET-1) by a specific endothelin-converting enzyme (ECE) (1) . ECE has been proposed to be a phosphoramidon-inhibitable metalloprotease, which has been detected in endothelial cells (ECs) (2, 3) and vascular smooth muscle cells (4) . Phosphoramidon (PA), a metalloprotease inhibitor, was reported to suppress bET-l-induced responses in vivo such as sudden death (5), hypertension (6, 7) , hemocon centration (8) and enhancement of vascular permeability (9) as well as found to inhibit ECE in vitro (10, 11) .
Although several inhibitors besides phosphoramidon were claimed to inhibit ECE, most of them did not inhibit ECE specifically and intensely. ECE was also inhibited by metal chelating agents; therefore, 5 mM EDTA inhibited ECE when the conversion occurred at pH 7.0 (12) . Asper gillomarasmine-A and -B (AM-A and -B), phytotoxins produced by several phytopathogeneous fungi (13) , are known to cause a disturbance of the water balance and wilting effects in plant leaves by their Fe 3+-chelating activ ity (14) . AM-A and -B also have abilities to inhibit an giotensin-converting enzyme (ACE) (15) . Recently, we have found that AM-A and -B, which were isolated from the cultured broth of an unidentified fungus N877, have an intense inhibitory activity against ECE from bovine endothelial cells. In the present study, we have further evaluated the pharmacological profiles of AM-A and -B in both in vitro and in vivo experiments, in contrast to the profiles of EDTA and PA.
MATERIALS AND METHODS

Animals and drugs
Male ICR mice (6 to 7-week-old; Charles River Japan, Inc., Atsugi) and male Sprague-Dawley rats (250-350 g, Charles River Japan, Inc.) were used.
Human ET-1, human bET-1, PA, E-64 and pepstatin A were purchased from the Peptide Institute, Inc. (Osaka). Rabbit IgG anti ET (15) (16) (17) (18) (19) (20) (21) and rabbit IgG F(ab')2 HRP were obtained from International Reagents Corp. 
Preparation of membrane ECE
ECs of a bovine aorta grown to a confluent monolayer were rinsed with phosphate-buffered saline (PBS, pH 7.4) and detached from the culture flasks by using 0.2% tryp sin. ECs were homogenized in ice-cold Buffer A, 50 mM sodium phosphate buffer (pH 7.0) containing 0.1 mM E 64, 1 mM DFP and 10 pM pepstatin A, with a glass homogenizer; and then the homogenate was centrifuged at 10,000 x g for 20 min at 41C. The precipitate was then sonicated for 3 min at 0 C , centrifuged at 100,000 x g for 60 min, resuspended in Buffer A by a sonicator and stored at -80 C.
ECE inhibition in vitro
After preincubation of the inhibitor with crude ECE (5 ,ug protein) in 124 it of 200 mM Tris-HC1 buffer (pH 7.0) containing 10 tM actinonin for 10 min, 100 nM bET-1 as a substrate was added to the reaction mixture. In some experiments, 10 pM ZnC12 or [1.8 mM CaC12 and 0.5 mM MgC12] were added to the reaction mixture to examine the effect of Zn2+ or [Ca 2+ and Mgt+]. Then the mixture was incubated at 37C for 4 hr. The reaction was stopped by heating at 1001C for 5 min. After cooling with ice, the amount of immunoreactive ET-1 (IR-ET-1) in the reac tion mixture was measured by EIA. Sandwich-EIA was employed using a rabbit IgG anti ET(15-21)-coated microtest plate. After blocking with 1 % BSA, the plate was reacted with standard ET-1 or the reaction mixture, followed by a reaction with rabbit IgG F(ab')2-HRP anti ET-1. The plate was washed with the buffer (0.1 % Triton X100 in PBS), and then the bound enzyme activity was measured with o-phenylenediamine as a chromogen. The assay showed no cross-reactivity with bET-1 at the con centration of 100 nM.
Effects on sudden death induced by bET-1 and ET-1 in mice Both AM-A and -B (Fig. 1) were suspended in saline containing 0.5% carboxymethylcellulose (CMC-saline). AM-A or -B at a dose of 10 or 50 mg/kg was intravenous ly administered to mice 10 min before the injection of bET-1 (25 nmol/kg, i.v.) dissolved in saline. This dose of bET-1 was reported to have an almost complete lethality in mice (5) . In control animals, CMC-saline was given as a vehicle. Mortality (%) and latency (sec) to death, as judged by the cessation of respiration, were measured up to 60 min after bET-1 injection. PA (2 mg/kg, i.v.), dis solved in CMC-saline, was employed as a positive refer ence compound.
To acertain the specificity for ECE, the effects on ET-1 induced lethality were also examined in mice according to the previously described method (5). AM-A (50 mg/kg), AM-B (50 mg/kg), EDTA (24 mg/kg), PA (2 mg/kg), or CMC-saline was intravenously injected; and 10 min later, ET-1 dissolved in saline was administered at the dose of 5 nmol/kg, i.v. Mortality and latency to death were then measured as described above. Measurement of plasma IR-ET-1 in mice CMC-saline, AM-A (50 mg/kg), EDTA (24 mg/kg) or PA (2 mg/kg) was intravenously given to mice 10 min prior to bET-1 injection (25 nmol/kg, i.v.); and there after, blood samples were collected by cardiac puncture at 5 min after bET-1 injection. The blood samples were placed in chilled tubes containing aprotinin (300 KIU/ml) and EDTA (2 mg/ml) and centrifuged at 2000 x g for 15 min at 41C. A plasma sample diluted ten times with PBS was added to the microtest plate. Plasma IR-ET-1 was measured by sandwich-EIA as described above.
Acute toxicity in male ICR mice Acute toxicities of AM-A and EDTA were evaluated in mice. AM-A and EDTA were intravenously given at doses of 125, 140, 165, 200 and 250 mg/kg for AM-A and at doses of 26, 28, 30 and 35 mg/kg for EDTA. The LD50 values based on 24-hr mortality were statistically analyzed by the Probit method. Six to eight mice were used for each dose of the compounds.
Effects on hemoconcentration
induced by bET-1 in mice CMC-saline, AM-A (30 mg/kg) or PA (10 mg/kg) was intravenously given to mice 10 min prior to bET-1 injec tion (10 nmol/kg, i.v.) as previously reported by Okumura et al. (8) . Blood samples were collected from the orbital sinus using glass capillaries precoated with heparin at 10 min after bET-1 injection. The hematocrit (Ht) was measured by centrifuging the blood at 12,000 rpm for 5 min. The effects of AM-A and PA on ET-1-induced hemo concentration were also examined in mice as previously described (8) . Ten minutes after the administration of i.v. saline, AM-A (30 mg/kg) or PA (10 mg/kg), ET-1 at a dose of 2.5 nmol/kg, i.v. was injected. Blood samples were collected to measure the hematocrit, as described above, 10 min after the ET-1 injection.
Effects on hypertension induced by bET-1 in anesthetized rats
Rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.). After tracheal intubation, polyethylene catheters were inserted into the left carotid artery and the left femoral vein for the continuous measurement of blood pressure and for drug administration, respectively. Ten minutes after the intravenous adminstration of CMC-saline, AM-A (30 mg/kg) or PA (10 mg/kg), bET-1
(1 nmol/kg) was injected to cause hypertension. Mean ar terial blood pressure (MBP) was recorded on a polygraph (RM-6000; Nihon Kohden, Tokyo) via a pressure trans ducer (TP-300T, Nihon Kohden) attached to the end of the catheter for 120 min after bET-1 injection. In some rats treated with AM-A, CMC-saline was injected instead of bET-1 for the assessment of the effect of AM-A alone on MBP.
Statistical analyses
Data are expressed as means±S.E. of observations. Mortality at 60 min after ET-1 or bET-1 injection was evaluated by the Fisher exact probability test. If an animal survived over 60 min, its latency was regarded as 3600 sec. Differences in latency, the Ht, plasma IR-ET-1 and MBP among the groups were determined by an un paired Student's t-test or a one-way analysis of variance with the Bonferroni modification. P values less than 0.05 were regarded as statistically significant. 
RESULTS
Inhibition of ECE
In the absence of Zn2+, AM-A, AM-B, PA and EDTA effectively inhibited ECE with IC50 values of 3.4, 2.5, 0.8 and 1.1 pM, respectively. When Zn2+ (10 pM) was added to the reaction mixture, AM-A, AM-B and EDTA lost their ECE inhibitory activities, but PA sustained its activ ity ( Table 1) . Addition of Mg2+ and Ca 2+ at the same con centration of those in Tyrode solution to the reaction mix ture did not affect the inhibitory activity of AM-A against ECE but attenuated that of EDTA (Table 1) .
Effects on sudden death induced by bET-1 and ET-1 in mice
Intravenous administration of bET-1 (25 nmol/kg) to mice caused a slower onset of sudden death with a mean latency to death of 663.6-932.3 sec (5 experiments) com pared to that caused by ET-1 (5 nmol/kg, mean latency =260 .9 sec) as observed in our previous report (5) . In bET-l-induced sudden death, although AM-A and -B failed to alleviate mortality, the two compounds signifi cantly prolonged the latency to death in a dose-depend ent manner at doses of 10 and 50 mg/kg, i.v. (Fig. 2 and Table 2 ). EDTA did not improve any parameters even at a dose of 24 mg/kg, i.v., while PA (2 mg/kg, i.v.) com pletely suppressed mortality (P<0.01).
These com pounds, however, did not provoke any mitigation in ET-1 (5 nmol/kg, i.v.)-induced sudden death (Table 2) . Elevation of plasma IR-ET-1 induced by bET-1 (25 nmol/kg, i.v.) and the effects of AM-A, EDTA and PA were examined 5 min after bET-1 injection in mice. As shown in Table 3 , the concentration of plasma IR-ET-1 reached 67.8 pg/ml at 5 min, which was not considered to be the maximum response, as observed in our previous report (5) . Pretreatment with AM-A (50 mg/kg, i.v.) or PA (2 mg/kg, i.v.) definitely lowered plasma IR-ET-I by 76.0% and 43.1 %, respectively, at 5 min after bET-I in jection, while EDTA (24 mg/kg, i.v.), in spite of showing ECE inhibition in vitro, did not. AM-A and PA at the same doses also suppressed the elevation of plasma IR ET-1 even at 15 min after the injection of bET-1 (data not shown).
Acute toxicity in male ICR mice
Mortality was measured at the dose range of 125-250 mg/kg, i.v. for AM-A and 26-35 mg/kg, i.v. for EDTA. The LD50 value of AM-A was calculated to be 159.8 mg/kg, i.v., which was much larger than that of EDTA (28.5 mg/kg, i.v.). This indicates the lower toxicity of AM-A as compared to EDTA.
Effects on hemoconcentration
induced by bET-1 in mice The injection of bET-1 (10 nmol/kg, i.v.) induced a significant increase in Ht, namely hemoconcentration, by 12.4% (Fig. 3, from 46 .50±0.43 to 52.25±0.89, P<0.01). The increase in Ht by bET-1 continued at least 120 min after the injection (8). Pretreatment with AM-A (30 mg/kg, i.v.) or PA (10 mg/kg, i.v.) significantly in hibited bET-l-induced hemoconcentration by 66.6010 for AM-A (P <0.01) and 39.1 % for PA (P <0.05) (Fig. 3) . Neither AM-A nor PA alone affected the basal Ht (data not shown).
The effects of AM-A and PA on ET-1-induced hemo concentration in mice were also examined to clarify the influence of these inhibitors on ET-1 degradation. ET-1 
Effects on hypertension induced by bET-1 in anesthetized rats
As shown in Fig. 4 , the injection of bET-1 (1 nmol/kg, i.v.) caused a progressive increase in MBP. Pretreatment with AM-A (30 mg/kg, i.v.) remarkably inhibited bET-1 induced hypertension; and in a later phase (60 min after bET-1 injection), it induced hypotension in spite of bET 1 treatment. AM-A alone, however, did not exert any sig nificant effects on basal MBP. PA at a dose of 10 mg/kg, i.v., which was higher than that required to inhibit bET 1-induced lethality, also attenuated the increase in MBP induced by bET-1 (Fig. 4) . 
DISCUSSION
ECE has been claimed to be a metalloprotease because ECE activities in vitro and in vivo are effectively blocked by a metalloprotease inhibitor, phosphoramidon. EDTA and EGTA, metal chelators, concentration-dependently inhibited EC activities in the homogenate of cultured bo vine aortic endothelial cells (2) . Several metal ions, such as Zn2+, Mn2+, Fe 2+ and Cot+, reactivated ECE once in activated by EDTA (10) . In the present study, addition of Zn2+ to the reaction mixture resulted in attenuation of ECE inhibition by AM-A, AM-B and EDTA (Table 1) . These chelators also inhibited ACE, which could be reversed by the addition of stoichiometric Zn2+ to the reaction mixture (15, 16) . These observations imply that the ECE inhibitory activities of AM-A, AM-B and EDTA are mainly consequences of their metal chelating activ ities.
Inhibition of ECE in vivo, however, differed among the metal chelators. As shown in Tables 2 and 3 , AM-A and -B significantly suppressed sudden death and elevation of plasma IR-ET-1 provoked by bET-1 in mice (AM-B was not tested in the study for IR-ET-1 measurement), but EDTA failed to inhibit these responses even at a dose of 24 mg/kg, i.v., which was the highest possible dose con sidering its marked toxicity (LD50=28.5 mg/kg, i.v.). Our present study also clearly demonstrates that EDTA lost its inhibitory activity against ECE in vitro in the presence of Ca2+ and Mg2+ at concentrations almost equivalent to those in plasma, while AM-A sustained its activity (Table 1 ). This indicates that EDTA would lose its ability to inhibit ECE as soon as it appeared in the blood, where Ca and several metal ions were abundant. Thus the intense metal chelating activity of EDTA would result not only in striking inhibition of ECE in vitro but also result in nonselective and rapid chelation of metal ions existing in the blood when intravenously admin istered to mice, leading to insufficient inhibition of ECE and to high toxicity in vivo. On the other hand, the che lating activity of AM-A with Ca 2' and Mg2+ was so weak that it could preserve the ability of the ECE inhibition in vivo with low toxicity.
In this connection, our previous study also demonstrat ed that inhibition of bET-l-induced lethality by PA was closely relevant to the decrement in plasma IR-ET-1 for mation (5) . In the present study, a causal relationship be tween the plasma IR-ET-1 level and the mitigation of bET I -induced lethality was observed between AM-A and EDTA and between PA and EDTA. The relationship be tween AM-A and PA, however, was reversed: At 5 min af ter bET-1 injection, PA lowered plasma IR-ET-1 less effec tively than did AM-A, whereas PA completely abolished sudden death, but AM-A did so incompletely. At 15 min after bET-1 injection, both compounds surely suppressed the elevation of plasma IR-ET-1 by the same degree (data not shown). These data indicate that plasma IR-ET-1 would not be a crucial factor in bET-l-induced sudden death; instead, tissue IR-ET-1 in the lung, vasculature and so on would also be important for bET-l-induced sudden death.
In the experiments of bET-l-induced hemoconcentra tion (Fig. 3) and hypertension (Fig. 4) , the doses of bET-1 employed were 10 and 1 nmol/kg, i.v., respectively, which were much lower than that employed in the bET-1 induced sudden death experiment (25 nmol/kg). In those cases, AM-A at a dose equal to that for the sudden death displayed sufficient inhibition of ECE followed by sig nificant attenuation of bET-1-induced hemoconcentra tion and hypertension. This suggests that AM-A would be able to suppress ECE almost completely followed by the attenuation of bET-l-induced phenomena when bET-1 as a substrate for ECE is very low in concentration. On the contrary, a higher dose of PA (10 mg/kg, i.v.) was re quired to obtain significant inhibition against these bET 1-induced reactions compared to that against the sudden death (2 mg/kg). Matsumura et al. (6) reported that they used 0.25 mg/kg/min of PA at least 30 min prior to bET 1 injection and thereafter over a 40-min experiment period, estimating that at least 10-20 mg/kg of PA is re quired for suppression of the pressor response. Since hemoconcentration (8) and hypertension (1) were report ed to be easily induced by a small amount of ET-1, these two responses would also be induced by a small amount of bET-1, as a precursor of ET-1. Accordingly, a small quantity of ET-1, which was converted from bET-1 despite ECE inhibition by PA at the lower dose of 2 mg/kg, i.v., was able to induce hemoconcentration and hypertension. In other words, complete inhibition of ET 1 production leads to prevention of the two reactions induced by bET-1. As for bET-l-induced sudden death, a high dose of bET-1 (25 nmol/kg, i.v.) is necessary to achieve complete lethality (5) . The LD50 value of bET-1 was estimated to be 21.0 nmol/kg, i.v., and the sudden death completely disappeared when the dose of bET-1 was decreased to 15 nmol/kg. These results indicate that bET-l-induced sudden death is vulnerable to changes in the amount of exogeneously given bET-1, i.e., that of ET-1 converted by ECE or that of ET-1 formation inhibit ed by PA.
In the present study, AM-A caused hypotension in a later phase after bET-1 injection, while AM-A alone did not. It has been reported that ET simulates atrial natriuretric peptide (ANP) (17) , which successively caused hemoconcentration (8) . ANP is also known as a hypotensive factor and is degraded by neutral endopepti dases (NEP). Since AM-A would inhibit NEP by its chelating activity, it would inhibit the degradation of ANP, which would lead to hypotension.
In mice, however, AM-A failed to increase the plasma ANP level at 60 or 120 min after bET-1 injection (data not shown). This indicates that the hypotension caused by AM-A in a later phase after bET-1 injection was not due to ANP and that other unknown factor(s) would be involved in the phenomenon.
Taking into consideration our findings showing that AM-A has a lower toxicity than EDTA, AM-A, as well as AM-B, is concluded to be a novel ECE inhibitor with dis tinct in vivo activity. Since AM-A and -B were ineffective in mitigating ET-1-induced responses (sudden death and hemoconcentration)
in vivo, alleviation of bET-1-in duced responses by these chelators was confirmed to be due to inhibition against ECE. These compounds can be utilized as pharmacological and enzymological tools to investigate the role of ECE and ECE itself.
